<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984226</url>
  </required_header>
  <id_info>
    <org_study_id>1343905</org_study_id>
    <nct_id>NCT04984226</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Veverimer on Muscle Mitochondrial Energetics and Physical Endurance in Persons With CKD</brief_title>
  <official_title>Randomized Cross-over Trial of Veverimer and Sodium Bicarbonate on Muscle Mitochondrial Energetics and Physical Endurance in Chronic Kidney Disease and Metabolic Acidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skeletal muscle metabolic health is critical for mobility and an underrecognized target of&#xD;
      metabolic acidosis in chronic kidney disease. Impaired muscle mitochondrial metabolism&#xD;
      underlies poor physical endurance increasing the risk of mobility disability. The proposed&#xD;
      project will use precise in vivo tools to study the pathophysiology of poor physical&#xD;
      endurance in a clinical trial treating metabolic acidosis among persons living with chronic&#xD;
      kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease (CKD) is highly prevalent affecting 14% of the U.S. population leading&#xD;
      to substantial morbidity and reduced quality of life. Older adults with CKD identify&#xD;
      maintenance of functional independence as their top priority. Skeletal muscle health is&#xD;
      critical for mobility and an underrecognized target of metabolic acidosis (MA) and protein&#xD;
      energy wasting in CKD. Skeletal muscle endurance provides a window into muscle metabolic&#xD;
      health and muscle quality. Muscle mitochondrial metabolism is central to muscle and walking&#xD;
      endurance providing energy from carbohydrates and fats to power repeated muscle contraction.&#xD;
      Investigators showed metabolic acidosis and muscle adiposity as the major determinants of&#xD;
      muscle mitochondrial function.&#xD;
&#xD;
      Metabolic acidosis (MA) is long believed to be the main mechanism leading to skeletal muscle&#xD;
      wasting and peripheral insulin resistance in CKD. Skeletal muscle mitochondrial metabolism is&#xD;
      considered a principal determinant of peripheral insulin sensitivity and muscle quality, but&#xD;
      little is known of the impact of MA on muscle mitochondrial function. Muscle mitochondrial&#xD;
      dysfunction leads to defective lipid metabolism augmenting adiposity and lipotoxic&#xD;
      intermediates resulting in insulin resistance, low endurance, and muscle atrophy. Using in&#xD;
      vivo 31Phosphorus Magnetic Resonance Spectroscopy (31P MRS) investigators showed that the&#xD;
      presence and severity of CKD is strongly associated with impaired muscle mitochondrial&#xD;
      capacity to generate ATP translating into poor walking endurance. Investigators also showed&#xD;
      MA and muscle adiposity are the major determinants of muscle mitochondrial function. Recently&#xD;
      a non-sodium polymer (veverimer) selectively binding hydrogen chloride in gastrointestinal&#xD;
      tract safely improved serum bicarbonate and meaningfully improved physical functioning in a&#xD;
      randomized clinical trial. Despite the importance of mitochondrial function to muscle health,&#xD;
      it is unknown if treatment of MA benefits muscle mitochondrial function, adiposity or&#xD;
      endurance in CKD.&#xD;
&#xD;
      The proposed project will use precise, in vivo 31P MRS and gold-standard testing of&#xD;
      peripheral insulin sensitivity by hyperinsulinemic euglycemic clamp to probe the&#xD;
      pathophysiology of MA and low endurance in a clinical trial of alkali therapy in CKD and MA.&#xD;
      We will compare veverimer or low-dose sodium bicarbonate to placebo in a multicenter&#xD;
      randomized, double-dummy placebo-controlled, cross-over trial design in 102 persons with&#xD;
      moderate-severe CKD and MA. First, the efficacy of 3-months of alkali therapy will be tested&#xD;
      comparing veverimer or low dose sodium bicarbonate versus placebo on muscle metabolic health&#xD;
      in a randomized crossover trial in MA. Second, Test the efficacy of 3-months of alkali&#xD;
      therapy comparing veverimer or low dose sodium bicarbonate versus placebo on improving&#xD;
      physical endurance in MA. The rationale is that identification of therapeutic targets for low&#xD;
      physical endurance will inform the development of pharmacologic interventions. Long term, it&#xD;
      is expected that strategies treating MA will improve exercise tolerance enabling effective&#xD;
      engagement in lifestyle interventions improving quality of life in CKD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle mitochondrial oxidative capacity by 31P MRS</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will use 31P MRS to evaluate the concentration of phospho-creatine (PCr) and other phosphate-energy carrier molecules in limb muscles. After one minute of basal resting measurements, patients will be asked to perform two knee extensions every three seconds against a resistance of 30 to 40% of the maximal voluntary contraction. The exercise protocol will last 90 seconds (a total of 60 knee extensions) followed by four minutes of rest. The exercise/rest cycle will be repeated three times. The intensity of the exercise decreases phosphocreatine (PCr) levels with minimal change in muscle pH. Spectra analysis was performed with AMARES from the jMRUI software package. Spectra are used to calculate the relative concentrations of inorganic phosphate (Pi), PCr, and ATP. The recovery of PCr after the exercise was fit with a monoexponential model that calculated the time constant tau (Ï„) in unit of seconds, which is the time to restore approximately 63% of the recovery response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity (SI) by insulin clamp</measure>
    <time_frame>12 weeks</time_frame>
    <description>Primary endpoint for the hyperinsulinemic euglycemic clamp testing will be insulin sensitivity defined as (glucose disposal rate - concentration of infused glucose)/(insulin concentration at steady state - fasting insulin concentration). Units are mg/min per microunit per milliliter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total work performed on cycle ergometry VO2</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total work will be obtained by cycle ergometry using standard protocol measuring oxygen uptake starting at 0 watts (W) at 60 rotations per minute (rpm) increasing by 25W every 2 minutes until volitional exhaustion adapting a prior protocol used in CKD patients. The primary measure will be total work completed (Joules).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>muscle work efficiency cycle ergometry</measure>
    <time_frame>12 weeks</time_frame>
    <description>joules/ml Oxygen(VO2 peak)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Walking endurance by 6-minute walk</measure>
    <time_frame>12 weeks</time_frame>
    <description>Meters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FACIT-F Fatigue (PRO)</measure>
    <time_frame>12 weeks</time_frame>
    <description>score on FACIT-F questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intermuscular fat by MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent intermuscular fat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 second sit to stand test</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of times patient can get up from sitting position over 30 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Fatigue (PRO)</measure>
    <time_frame>12 weeks</time_frame>
    <description>score on NIH PROMIS Fatigue questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Muscle mitochondrial respiration from in situ high resolution respirometry of muscle biopsy tissue</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will determine mitochondrial respiration and oxidative stress under different respiratory states including subsaturating and saturating ADP (state 3), using a combination of complex I (glutamate + malate) and complex II (succinate) substrates, state 4 respiration (proton leak in the absence of ADP and the presence of oligomycin), and fully uncoupled respiration using FCCP. The assay for mtH2O2 production is based on the rate of production of the fluorescent molecule, resorufin, when Amplex Red reacts with H2O2 as described. We a priori select mtH2O2 of reverse electron transport (succinate as substrate in the absence of ADP) as our primary endpoint given the evidence that complex I is the predominant source of mtROS during aerobic exercise. Units are pmol/sec.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory cytokines. TNF-alpha and IL-6</measure>
    <time_frame>12 weeks</time_frame>
    <description>Inflammatory cytokines. Units pg/ml.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Metabolic Acidosis</condition>
  <condition>Fatigue</condition>
  <condition>Physical Endurance</condition>
  <condition>Insulin Resistance</condition>
  <condition>Mitochondrial Energetics</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Veverimer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 grams daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5mEq/kg lean mass daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium bicarbonate placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>cornstarch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Veverimer placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veverimer</intervention_name>
    <description>Veverimer is an orally administered, non-absorbed polymer selectively binding hydrochloric acid from the gastrointestinal tract safely elevating endogenous serum bicarbonate levels.</description>
    <arm_group_label>Veverimer placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>Standard baking soda delivering an exogenous alkali load to increase serum bicarbonate.</description>
    <arm_group_label>Sodium bicarbonate placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veverimer placebo</intervention_name>
    <description>microcrystalline cellulose, National Formulary Grade</description>
    <arm_group_label>Veverimer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium bicarbonate placebo</intervention_name>
    <description>Cornstarch</description>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate-severe CKD determined by eGFR &lt;60ml/min per 1.73m2 by CKD EPI equation on at&#xD;
             least 2 consecutive occasions.&#xD;
&#xD;
          -  Metabolic acidosis defined as bicarbonate level&lt;23 on two consecutive occasions.&#xD;
&#xD;
          -  Age 30 to 85 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes managed with insulin treatment&#xD;
&#xD;
          -  Poorly controlled diabetes (HgbA1c&gt;10%)&#xD;
&#xD;
          -  History of persistent hyperkalemia (K&gt;5.4)&#xD;
&#xD;
          -  Chronic treatment with renal replacement therapy&#xD;
&#xD;
          -  History of aortic dissection or severe valvular heart disease&#xD;
&#xD;
          -  Exercise induced angina&#xD;
&#xD;
          -  Uncontrolled cardiac dysrhythmia&#xD;
&#xD;
          -  Oxygen dependent COPD&#xD;
&#xD;
          -  Symptomatic claudication&#xD;
&#xD;
          -  End stage liver disease&#xD;
&#xD;
          -  Mobility disability defined as inability to walk without human assistance&#xD;
&#xD;
          -  Dementia or psychosis&#xD;
&#xD;
          -  Patients who cannot consent&#xD;
&#xD;
          -  Active use of IV drugs&#xD;
&#xD;
          -  Non-english speaking&#xD;
&#xD;
          -  History of transplant&#xD;
&#xD;
          -  Implants that prohibit MRI measurements or trauma involving metal fragments&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Expectation to start dialysis during the course of study.&#xD;
&#xD;
          -  Any condition which in the judgement of the clinical investigator places the&#xD;
             participant at risk from participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baback Roshanravan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Gamboa, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baback Roshanravan, MD</last_name>
    <phone>530-754-0893</phone>
    <email>broshanr@ucdavis.edu</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Baback Roshanravan</investigator_full_name>
    <investigator_title>Associate Professor, Nephrology</investigator_title>
  </responsible_party>
  <keyword>Metabolic acidosis</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>within 18 months after the conclusion of the study. This data will be available indefinitely</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

